>>     >>   Sanofi Pasteur launches pediatric vaccine Hexaxim in India

Sanofi Pasteur launches pediatric vaccine Hexaxim in India

Hexaxim provides protection against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenza B and hepatitis B, said Sanofi Pasteur


  |  Updated On : November 24, 2016 09:17 PM
Medicines - Representative Image (Image Source:Getty)

Medicines - Representative Image (Image Source:Getty)

New Delhi :  

Sanofi Pasteur, the vaccines global business unit of Sanofi, on Thursday announced the launch of paediatric 6-in-1 vaccine, Hexaxim in India; which is capable of providing protection against six major childhood diseases.

The ready-to-use fully liquid vaccine provides protection against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenza B and hepatitis B, Sanofi Pasteur said in a statement.

It is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age, it added.

Sanofi Pasteur India, Nepal and Sri Lanka Country Head Jean-Pierre Baylet said, "Hexaxim brings to life Sanofi Pasteur's mission to improve human health by developing superior innovative vaccination solutions against infectious diseases."

"Given the large influx of patients met by pediatricians in India, Hexaxim will offer convenience and ensure consistency in administering the right dose of each antigen every single time," he added.

Hexaxim, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested, Sanofi Pasteur said.

Each dose of Hexaxim takes 24 to 36 months for manufacturing, of which 70 per cent of the time is spent on quality tests, it added.

Sanofi Pasteur is the vaccines global business unit of pharma major Sanofi.

First Published: Thursday, November 24, 2016 08:39 PM


Download the News Nation Mobile App and stay connected with top stories from India and around the world. Available on Android and IOS.


NEXT STORY